Drugs / IHV01
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04041674 | Mar → Sep 2022 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 1 | NCT04658667 | Feb 2022 → Jul 2024 | HIV infectious disease | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 1 | NCT03505060 | Jan → May 2019 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IHV01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04041674 ↗ |
| Modality | Vaccine | “IHV01 protein vaccine” NCT03505060 ↗ |
| Route | Intramuscular | “Administered by intramuscular injection in the deltoid.” NCT03505060 ↗ |